XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Acquisition and Equity-Method Investment - Change in the Carrying Value of Equity Method Investment (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jul. 02, 2023
Jun. 30, 2024
Jul. 02, 2023
Schedule of Changes in Carrying Value of Investments [Roll Forward]        
Beginning carrying value reported in Equity-method investments     $ 11,637  
Ending carrying value reported in Equity-method investments $ 8,029   8,029  
Haleon [Member]        
Schedule of Changes in Carrying Value of Investments [Roll Forward]        
Beginning carrying value reported in Equity-method investments 7,922 $ 10,980 11,451 $ 10,824
Carrying value of shares sold 0 0 (3,312) 0
Dividends (157) (88) (157) (88)
Currency translation adjustments and other [1] 1 185 (130) 274
Basis difference adjustments and amortization [2],[3] (1) 0 (101) (1)
Pfizer share of Haleon investee capital transaction [2],[4] (91) 0 (91) 0
Pfizer share of Haleon earnings [2] 121 151 136 219
Ending carrying value reported in Equity-method investments $ 7,796 $ 11,228 $ 7,796 $ 11,228
[1] See Note 6.
[2] Included in Other (income)/deductions––net.
[3] Adjustments in the six months ended June 30, 2024 are associated with (i) the impact of Haleon’s brand divestitures and impairments of intangible assets and (ii) changes in Haleon’s tax rates on intangible asset-related deferred tax liabilities. See Note 4.
[4] Amounts for the three and six months ended June 30, 2024 relate to Pfizer’s share of an investee capital transaction recognized by Haleon for treasury stock Haleon purchased in the first quarter of 2024.